https://www.selleckchem.com/pr....oducts/Isoprenaline-
HBsAg decline in HBeAg patients treated with NAs or PEG-IFN was 0.418 or 1.217 log IU/mL (P0.0001) at week 48; whereas HBsAg decline was 0.176 or 0.816 log IU/mL (P0.001) in HBeAg patients. HBsAg at baseline and week 24 were strong predictors of "low HBsAg at week 48". Long term anti-viral therapy inhibits HBV replication effectively in ALT2×ULN CHB patients. PEG-IFN therapy is recommended for HBeAg patients with baseline HBsAg4.37 log IU/ml and HBeAg patients with baseline HBsAg2.66 log IU/ml to a
Like
Comment
Share
